Researchers with the National Institutes of Health (NIH) has identified in a recent study which brain circuits are essential for visual acuity and how they may be affected by retinal cell damage. The ...

Jay Chhablani, MD, from the University of Pittsburgh Medical Center's Vision Institute discusses 3D choroidal vessel segmentation technology. Using advanced Plex elite Zeiss swept-source OCT imaging, ...

ViGeneron has rebranded to VeonGen Therapeutics to reflect its evolution into a “clinical-stage genetic medicine company focused on developing transformative gene therapies for patients with high ...

W. L. Gore and associates (Gore) announced the launch of its silicone-free GORE IMPROJECT Plunger for 0.5-mL pre-filled syringes that are designed specifically to facilitate the delivery of ophthalmic ...

The Retina World Congress 2025, led by President Barry Kuppermann, represents a pivotal moment in ophthalmological innovation, bringing together international retina specialists to discuss ...

Dilsher S. Dhoot, MD, discusses how second-generation anti-VEGF therapies like aflibercept 8 mg and faricimab demonstrate superior efficacy and durability in treating neovascular age-related macular ...

Dilsher S. Dhoot, MD, discusses how newer anti-VEGF treatments, particularly aflibercept 8 mg, can provide improved anatomic outcomes and extended treatment intervals for patients with neovascular age ...

The second episode transitions to diabetic macular edema (DME) treatment using next-generation anti-VEGF agents. Dr. Dhoot presented a case with large cystoid changes and intraretinal fluid that ...

Dilraj S. Grewal, MD, FASRS, an associate professor of ophthalmology at Duke Eye Center, provides an in-depth overview of the current state of research and treatment innovations. "It's an exciting ...

David Tanzer, MD, Lexitas Pharma Services' CMO, met up with Modern Retina® to chat during the 2025 Retina World Congress annual meeting. "This has been an amazing conference, and congratulations to ...

Sophie X. Deng, MD, PhD, FARVO, has stepped into the role as the new 2025-2026 Association for Research and Ophthalmology (ARVO) president. Deng has been part of ARVO for more than 20 years, is a ...

EyePoint Pharmaceuticals recently announced the enrollment and randomization of its phase 3 LUGANO trial (NCT06668064) of DURAVYU for the treatment of wet age-related macular degeneration (wet AMD).